Study guide

MacTel and radiation retinopathy

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

MacTel and radiation retinopathy

Key Takeaways Explain This Topic AI

MacTel type 2 involves neurodegeneration as well as vascular changes, and cavitation differs from ordinary exudative oedema.

Treat neovascular complications separately from the underlying nonproliferative MacTel process.

Radiation retinopathy and neuropathy depend on tissue exposure and latency, with treatment directed to the complication.

Last updated: October 2026

Macular Telangiectasia (MacTel): Type 1 vs. Type 2

Macular telangiectasia comprises two clinically, epidemiologically, and pathologically distinct entities:

MacTel Type 1 (Unilateral Aneurysmal Telangiectasia)

Demographics: Unilateral in 98% of cases; striking predilection for males in the fourth to fifth decades of life (mean age ~40 years). Considered an abortive or localized macular variant of Coats disease.

Pathophysiology: Primary vascular telangiectasia of the temporal macular capillary network. Dilated, ectatic capillaries, microaneurysms, and localized lipid exudation produce chronic macular oedema and exudative visual loss.

Clinical Presentation: Metamorphopsia and moderate visual loss ( 6 / 12 6/12 6/12 to 6 / 36 6/36 6/36 ). Slit-lamp biomicroscopy reveals prominent telangiectatic capillaries and aneurysms in the temporal half of the macula, surrounded by circinate rings of yellow lipid hard exudates and cystoid macular oedema.

Therapeutic Response: Responds favourably to targeted focal argon laser photocoagulation directed at leaking aneurysms, as well as intravitreal anti-VEGF or dexamethasone implants.

MacTel Type 2 (Bilateral Idiopathic Perifoveal Telangiectasia)

Demographics: Bilateral, symmetric, acquired disorder manifesting in the fifth to seventh decades (mean age 55–60 years). Equal gender distribution or slight female predominance. Highly associated with systemic metabolic syndrome, hypertension, and type 2 diabetes.

The Paradigm Shift: A Neurodegenerative Disorder: Extensive clinicopathological research demonstrates that MacTel Type 2 is NOT a primary retinal vascular disease . Rather, it is a primary neurodegenerative disease of Müller glial cells . Loss of Müller cell footplates in the fovea leads to secondary depletion of macular xanthophyll pigments (lutein and zeaxanthin), progressive photoreceptor apoptosis, and tertiary microvascular ectasia and cavitation.

Multimodal Clinical Features:

Biomicroscopy: Subtle loss of retinal transparency (grayish opalescence) often most prominent to the temporal juxtafoveolar area ; superficial refractile crystalline deposits in ~50% of eyes; dilated, blunted right-angled venules that plunge perpendicularly into deep retinal layers; late stellate hyperpigmentation plaques (pigment hyperplasia).

Absence of Lipid: In sharp contrast to MacTel Type 1 and diabetic retinopathy, prominent lipid hard exudates are completely absent in uncomplicated MacTel Type 2.

Optical Coherence Tomography (SD-OCT): Demonstrates the characteristic "ILM Drape" —the internal limiting membrane remains structurally intact, draping over empty, hyporeflective cavitations in the inner and outer retina without overall retinal thickening. Focal disruption of the ellipsoid zone (EZ) and external limiting membrane occurs, progressing to full-thickness macular holes (which lack surrounding subretinal fluid cuffs).

Fluorescein Angiography: Early telangiectatic capillary dilatation limited to the temporal perifoveolar network; late diffuse ectatic hyperfluorescent staining without classical petaloid cystoid pooling.

Confocal Blue Reflectance: Reveals a distinct, oval zone of hyper-reflectance centered temporally to the fovea.

Dual-Wavelength Autofluorescence: Demonstrates characteristic loss of normal central luteal pigment absorption.

Complications & Therapy:

Non-Neovascular Stage: Anti-VEGF is not routine treatment for the non-neovascular neurodegeneration; avoid destructive macular laser. Neither addresses the underlying photoreceptor loss. Emerging therapy: Encapsulated cell biodelivery implants secreting Ciliary Neurotrophic Factor (CNTF / NT-501) significantly slow photoreceptor loss.

Neovascular Stage: Secondary subretinal choroidal/retinal neovascularisation (SRNV / CNV) develops in ~10% to 15% of eyes, causing acute subretinal haemorrhage. Unlike the non-neovascular phase, secondary CNV responds dramatically to intravitreal anti-VEGF injections.

Radiation Retinopathy & Radiation Optic Neuropathy

Radiation retinopathy is a delayed-onset, slowly progressive, occlusive microangiopathy resulting from exposure of the retina to ionizing radiation.

Etiology & Dosimetry

Radiation Sources:

Ophthalmic Plaque Brachytherapy: Iodine-125 ( 125 I ^{125}\text{I} 125 I ), Ruthenium-106 ( 106 Ru ^{106}\text{Ru} 106 Ru ), or Palladium-103 ( 103 Pd ^{103}\text{Pd} 103 Pd ) episcleral plaques utilized for the treatment of uveal melanoma, circumscribed choroidal haemangioma, or retinoblastoma.

External Beam Radiotherapy (EBRT) & Particle Beam Therapy: Proton beam irradiation, stereotactic radiosurgery (Gamma Knife / CyberKnife), or fractionated EBRT for head, neck, paranasal sinus, nasopharyngeal, or orbital malignancies.

Radiation Threshold & Latency:

Risk depends on total dose, fractionation, irradiated retinal volume, tumour location, diabetes and other treatment. Published series do not establish one universally safe retinal threshold or a fixed retinopathy percentage for every eye receiving the same nominal dose.

Latency Period: Characteristically delayed, with clinical manifestations typically emerging between 6 months and 3 years (peak onset at 18 to 36 months ) post-irradiation.

Accelerating Factors: Systemic hypertension, diabetes mellitus, and concurrent chemotherapy (e.g., 5-fluorouracil, cisplatin) significantly lower the radiation tolerance threshold and accelerate disease onset.

Molecular Pathology & Fundus Features

Ionizing radiation induces double-stranded DNA breaks in slowly dividing vascular endothelial cells, provoking cellular senescence, endothelial swelling, and apoptosis. The microvascular sequelae are clinically and angiographically identical to diabetic retinopathy : Ionizing Radiation ⟹ Endothelial Apoptosis ⟹ Capillary Occlusion ⟹ Severe Retinal Ischaemia ⟹ VEGF Upregulation \text{Ionizing Radiation} \implies \text{Endothelial Apoptosis} \implies \text{Capillary Occlusion} \implies \text{Severe Retinal Ischaemia} \implies \text{VEGF Upregulation} Ionizing Radiation ⟹ Endothelial Apoptosis ⟹ Capillary Occlusion ⟹ Severe Retinal Ischaemia ⟹ VEGF Upregulation

Clinical Signs: Cotton-wool spots (nerve fibre layer infarcts), microaneurysms, telangiectatic vessels, intraretinal flame and blot haemorrhages, hard exudates, and radiation macular oedema (RMO) .

Proliferative Complications: Extensive capillary non-perfusion on fluorescein angiography stimulates secondary neovascularisation of the disc (NVD), retina (NVE), and iris (rubeosis iridis), leading to vitreous haemorrhage and tractional retinal detachment.

Radiation Optic Neuropathy (RON): Occurs when the anterior optic nerve receives > 50 Gy >50\,\text{Gy} > 50 Gy ; presents with sudden, painless, catastrophic visual loss, swollen hyperaemic optic disc, peripapillary splinter haemorrhages, and subsequent optic atrophy.

Evidence-Based Management Protocols

Intravitreal Anti-VEGF Therapy: First-line treatment for radiation macular oedema (RMO). Anti-VEGF injections (aflibercept, ranibizumab, bevacizumab) administered on a proactive treat-and-extend schedule significantly decrease central foveal thickness and stabilize visual acuity.

Prophylactic Anti-VEGF Therapy: Selected cohort evidence supports scheduled injections after plaque treatment in defined populations. Interpret the comparator, follow-up and visual endpoint; this does not establish one compulsory prophylactic regimen for all forms of ocular irradiation.

Intravitreal Dexamethasone Implants: Effective adjuvant therapy, particularly in vitrectomised or refractory eyes.

Laser : Treat retinal neovascularisation and selected severe ischaemic complications according to specialist assessment. Nonperfusion alone does not impose a universal prophylactic laser rule.

Management Depends on Stage and Jurisdiction

Selected Coats disease without leakage threatening vision can be observed; leaking telangiectasia may need laser or cryotherapy, and detached retinas may require specialised drainage or surgery. Stage alone does not prescribe an identical operation. MacTel type 2 is primarily neurodegenerative with characteristic vascular and outer-retinal changes; anti-VEGF is used for associated neovascular complications, not routine treatment of non-neovascular cavitation. ENCELTO, an encapsulated cell implant delivering ciliary neurotrophic factor, received US FDA approval for adults with idiopathic MacTel type 2 on 5 March 2025. This is a US authorisation, not proof of European availability; verify local access. See the FDA approval . Radiation injury depends on dose, fractionation, field and latency; preventive injection series do not guarantee absence of retinopathy.